Vismodegib

CHEMBL473417 Phase 4 Approuvé Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

421.3 g/mol

LogP

3.8

Phase

4

This targeted therapy blocks the Hedgehog signaling pathway, which is abnormally activated in most basal cell carcinomas, and is used to treat locally advanced or metastatic basal cell carcinoma (a type of skin cancer) that cannot be treated with surgery or radiation. It is taken as a daily oral capsule. It causes severe birth defects and is absolutely contraindicated during pregnancy; severe muscle spasms and hair loss are also very common side effects.

Masse moléculaire

421,3000 g/mol

LogP

3,80

TPSA

84,50 Å²

Règle des 5 de Lipinski

Conforme

Aires thérapeutiques

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Non-Small Cell Lung Cancer Melanoma Lymphoma Breast Cancer Prostate Cancer Colorectal Cancer Leukemia

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Structure 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

CS(=O)(=O)c1ccc(C(=O)Nc2ccc(Cl)c(-c3ccccn3)c2)c(Cl)c1

InChI

InChI=1S/C19H14Cl2N2O3S/c1-27(25,26)13-6-7-14(17(21)11-13)19(24)23-12-5-8-16(20)15(10-12)18-4-2-3-9-22-18/h2-11H,1H3,(H,23,24)

Molecular Formula

C19H14Cl2N2O3S

HBD / HBA

1 / 4

Liaisons Rotatives

4

Atomes Lourds

27

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Foire aux questions

This targeted therapy blocks the Hedgehog signaling pathway, which is abnormally activated in most basal cell carcinomas, and is used to treat locally advanced or metastatic basal cell carcinoma (a type of skin cancer) that cannot be treated with surgery or radiation. It is taken as a daily oral capsule. It causes severe birth defects and is absolutely contraindicated during pregnancy; severe muscle spasms and hair loss are also very common side effects.

Yes, Vismodegib is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL473417. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 24776445. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

Vous cherchez des informations accessibles aux patients ?

Vismodegib sur PillFYI

Structure

Données Clés

Formule: C19H14Cl2N2O3S
Synonymes: 1

Liens externes

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Avertissement médical

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.